| Name | Title | Contact Details |
|---|
Biomedical International is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
With roots dating back to the 1970s, we are the most experienced provider of hospice care in Michigan. Currently serving more than 1,700 patients daily, in 56 counties, we`re also the largest in our state, and among the largest recognized 501c3 non-profit advanced illness management organizations in the nation. We provide care for all—regardless of age, diagnosis, or ability to pay. Last year, our commitment extended $4 million beyond what was reimbursed by insurance. Because we welcome those who are uninsured, or whose treatment is more expensive than what other hospices can provide, we depend on the financial support of our donors for the treatments, medications, services, grief support, and spiritual care of patients and families in need.
MakroCare is a Newark, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
T1D Exchange, a nonprofit organization, is a dynamic, multi-purpose, real-world patient data platform designed to accelerate all aspects of drug and device development. T1D Exchange has established a unique model to speed better treatments, therapies and research for type 1 diabetes (T1D). The Exchange consists of an integrated Clinic Network of 65+ clinics across the U.S., a Clinic Registry of 26,000 well-characterized patients, a Biorepository, and Glu, an online community with mobile capabilities for people touched by type 1 diabetes. The T1D Exchange fosters faster and more fluid information transfer and sharing among diabetes patients, physicians, researchers, and pharma, medical device, education, and outreach organizations.